Clinical Trials Logo

Clinical Trial Summary

Urinary tract infections (UTIs) are a common cause of bacteremia and serious bacterial infections in young children (2-24 months of age). Because these children are usually unable to say what symptoms they are experiencing, UTIs are diagnosed through testing. Current testing of urine samples require a catheter or suprapubic aspiration performed for urine collection for infections markers to be reliable. Bag specimens often have varying results that can be poor in sensitivity and specificity depending on what component of the urine test one is looking at. Catheter and aspiration testing can be anxiety-provoking to parents, be painful for patients and even introduce bacteria into the bladder. An antimicrobial peptide called alpha human defensin-5 (HD5) is produced by the uroepithelium in response to infection. HD5 has been studied in the urine and does increase in actual UTIs. This study will look at children 1 to 24 months of age and again study levels of HD5 in culture positive UTIs versus urine negative for UTI. This study will also determine if collection method alters HD5 levels. We will measure HD5 levels in the urine from a bag specimen and a catheter specimen in the same patient.

Our primary objective is to determine the sensitivity and specificity of HD5 measured in urine collected by bag and catheter in the same patient for the diagnosis of UTI in children between the age 1 to 24 months presenting with febrile illness and suspected UTI.


Clinical Trial Description

Pediatric urinary tract infections (UTIs) are a common diagnosis and account for greater than 500,000 emergency department (ED) visits each year in the US. Although prevalence varies by age, gender, ethnicity and circumcision status, the overall prevalence is cited between 5% to 13.8%. UTIs also account for a large number of pediatric hospital admissions with up to 50,000 children admitted per year, 40% of which occurring in children under the age of 1 year. In children under the age of two, diagnosis of UTI is difficult as patients are unable to verbalize complaints and often present with only fever or other nonspecific symptoms such as vomiting. UTIs are the leading cause of occult bacteremia and serious bacterial infection in the 2-24 month age range.

A definitive diagnosis of UTI is made when a patient has pyuria and/or bacteriuria with a positive urine culture. For non-toilet trained children who have urine collected by either suprapubic aspiration (SPA) or bladder catheterization, a urine culture is considered positive if a single uropathogenic organism of at least 50,000 colony forming units (CFU) per mL is recovered. Identification of a uropathogen by culture can take up to 48 hours to be completed which delays treatment and risks progression of infection if antibiotics are not given empirically. Commonly, clinicians use urine microscopy and dipstick for quick diagnosis to enable early empiric treatment of UTIs. However, the components of the urinalysis are limited in sensitivity and specificity even for specimens of high quality such as those obtained by catheterization or suprapubic tap. The main components of urine dipstick testing are leukocyte esterase (LE) and nitrite levels in urine. The LE test has a sensitivity of 94% when combined with clinical suspicion for UTI, but a specificity of only 83%. False positives for UTI occur when LE is positive in the child who has pyuria for other reasons besides infection, for example, in urethritis or Kawasaki disease. False negatives can occur in young children because the pattern of more frequent urination allows less time to mount an adequate inflammatory response to bacteria. Nitrites have a low sensitivity in young children (53%) due to frequent voiding not allowing sufficient time (up to 4 hours) for production of nitrites by bladder-dwelling bacteria; however, specificity is high (98%) making this a good test to rule in UTI. Sensitivity and specificity of urine microscopy for WBCs and bacteria are worse than for LE with pyuria (5 or more WBC/high power field on a spun sample or >10 WBC/hpf on an un-spun sample) having a sensitivity and specificity of 73% and 81% respectively. Presence of bacteria on microscopy has a sensitivity and specificity of 81% and 83% respectively. The resulting over- and under-treatment for false positive and negative urinalyses leads to increased costs, antibiotic resistance and unnecessary adverse events from antibiotics. The inaccuracy of the traditional urinalysis on bagged urine samples is much greater than for catheter specimens. These specimens suffer from false positives results for leukocyte esterase and cultures at rates up to 75-88% because of contamination by urogenital flora and white blood cells present on the perineum.

As a result of the poor performance characteristics of routine urinalyses on bag specimens, a sample obtained by catheterization in children who are not yet toilet-trained is required even for UTI screening. This is invasive and painful for the child, causes anxiety for the family, leads to urethral trauma and can even introduce bacteria into the urinary system. Recent research describes a new two-step technique of obtaining urine samples of screening for UTI on these young patients. First, a bagged urine sample is taken, and if suspicious for UTI by urinalysis, the patient then is catheterized for culture. One study showed that this technique decreased the number of catheterizations by 33%; however, given the low specificity of the urinalyses on bag specimens, there is still substantial room for reductions in unnecessary bladder catheterizations.

New urinary biomarkers hold promise to improve screening accuracy for UTIs. Watson et al. investigated antimicrobial peptides (AMPs) as urinary biomarkers of UTIs in children. One specific AMP, derived from the epithelium, is human alpha-defensin 5 (HD5). This AMP is produced by intestinal Paneth cells, the female genital tract and the uroepithelium. HD5 was found to have mean concentration significantly higher in the urine from culture-positive compared to culture-negative specimens. When used in combination with LE, HD5 increased the specificity of the LE-only test by 6% without decreasing the sensitivity (97% for LE > trace). This study determined the optimal cut-off value of 174 pg/mg creatinine to declare sample positive. Because HD5 is not derived from white blood cells, its presence is not affected by the presence or absence of WBCs in the urine to accurately identify urinary inflammation. While the authors of this study examined results from both clean-catch and catheterized specimens, they did not analyze samples collected by both techniques from the same patient.

Identification and validation of biomarkers with improved performance characteristics could reduce over-treatment of UTIs; validating such biomarkers on bag urine specimens has the further benefit of reducing the need for catheterization to provide urine to screen for UTI in a relatively unselected population of young children who have fever without a focus. We propose to compare the use of HD5 in bag versus catheter urine samples on children 1 to 24 months of age to determine if the biomarker has similarly high sensitivity and specificity to the original study in both specimen types. Eliminating the need for urine culture would also save on costs for children whose rapid testing does not suggest UTI. Reducing the number of catheterizations performed on young children will decrease the number of painful procedures, prevent introduction of bacteria in the urinary tract and decrease parental anxiety. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03163394
Study type Observational
Source Le Bonheur Children's Hospital
Contact
Status Terminated
Phase
Start date April 23, 2017
Completion date June 10, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04495699 - Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
Terminated NCT05254808 - EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care Phase 3
Completed NCT03680612 - Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI Phase 2
Completed NCT03282006 - Treating Pyelonephritis an Urosepsis With Pivmecillinam Phase 4
Completed NCT03526484 - The Utility of Urinalysis Prior to In-Office Procedures N/A
Completed NCT05397782 - Effects of Flourish on Recurrent Urinary Tract Infection N/A
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03687255 - Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections Phase 3
Recruiting NCT05227937 - Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT03131609 - Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
Completed NCT01911143 - A Retrospective, Blinded Validation of a Host-response Based Diagnostics N/A
Completed NCT01333254 - A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients N/A
Terminated NCT00594594 - Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury Phase 1
Completed NCT00216853 - A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection N/A
Completed NCT00787085 - The Significance of Funguria in Hospitalized Patients N/A
Completed NCT05719753 - The Effectiveness of a Bacteriophobic Coating on Urinary Catheters N/A
Recruiting NCT05415865 - The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder Phase 3
Not yet recruiting NCT05880329 - DIagnoSing Care hOme UTI Study
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine